In Ohio, the Cleveland Clinic joined the Circulating Cell-free Genome Atlas, a national clinical trial that is looking for 7,000 cancer patients and 3,000 healthy patients in the U.S. Their goal is to analyze DNA and RNA in the blood and build a database that will help with detecting cancer early on when it is easier to cure. Researchers believe that using genome sequencing from blood samples could possibly replace x-rays for early cancer detection. Funded by a company in California, GRAIL, Inc., the project will be looking for molecule patterns in the blood for specific types of cancers.
Latest article
Not PLA‑ying dead: Bioplastic skulls replace gory antler mounts
In Utah, Bucks N Bull Skulls is using bioplastic polylactic acid filament to 3-D print animal skulls for mounting antlers – an alternative that...
Funding flatlines: Meatable closes up shop
In the Netherlands, cultivated meat pioneer Meatable has failed to secure sufficient funding and is winding down operations. The company had been operating a...
“Sound” investment: Biobased acoustic panel maker Aisti receives €20 million EIB loan
In Finland, sustainable acoustics products firm Aisti has received a €20 million (US$23.4 million) loan from the European Investment Bank to scale production of...